Portfolio analysis of COVID-19-related patents using CRITIC-based TOPSIS approach

Many firms are unaware of which patent is comparatively more important in their patent portfolio. A firm needs to prioritize patents in terms of effective management of its patent portfolio and efficient allocation of resources. The COVID-19 pandemic was one of the most impactful disasters affecting daily human life in the last century. It is critical to evaluate and prioritize technologies developed to reduce the impact of this pandemic. To this end, patents related to COVID-19 are prioritized with the CRITIC-based TOPSIS approach in this study. 935 patents-related data were obtained from the USPTO (United States Patent and Trademark Office) patent database. To the best of the authors' knowledge, there is no study in the literature that uses the CRITIC-based TOPSIS approach to prioritize patents for the COVID-19 pandemic. The results of this study showed decision-makers and investors can consider technologies related to anti-infectives, medicinal preparations containing organic active substances, and medicinal preparations with a special physical form as investment options. © 2024, IGI Global. All rights reserved.